UK government backs modernised gene therapy definitions following MHRA consultation

Proposed amendments to the Human Medicines Regulations 2012 would clarify how certain synthetic nucleic acid medicines and genome-editing technologies are classified, subject to parliamentary approval.
On 19 November 2026, the UK government confirmed its support for proposed changes to the legal definition of gene therapy medicinal products following a consultation led by the Medicines and Healthcare products Regulatory Agency and the Department of Health in Northern Ireland.
The amendments would clarify the regulatory classification of certain synthetic nucleic acid therapies and sequence-specific genome-editing technologies, but implementation remains subject to international notification procedures and parliamentary approval.
Field | Content |
Alert Type | Industry Update |
Organisation(s) | UK government; Medicines and Healthcare products Regulatory Agency; Department of Health in Northern Ireland |
Industry Segment | Advanced therapy medicinal products; gene therapies; pharmaceutical regulation |
Development Type | Government-backed proposal to amend the legal definition of gene therapy medicinal products |
Therapy Area(s) | Gene therapy; genetic medicine; advanced therapies; genome editing |
Geography | United Kingdom |
Affected Stakeholders | Gene therapy developers; biotechnology and pharmaceutical companies; regulatory affairs teams; researchers; healthcare organisations; patients |
What Happened | The UK government confirmed plans to amend the definition of gene therapy medicinal products under the Human Medicines Regulations 2012 following an MHRA-led consultation. The government reported that 83% of respondents supported the proposals. |
Why It Matters | The proposed revision aims to reduce uncertainty over whether emerging synthetic nucleic acid products and sequence-specific genome-editing treatments fall within the established advanced therapies regulatory framework. |
Supporting Context | Existing legal definitions were developed when genetic medicine technologies were less diverse. The proposed approach would consider transcription or translation of recombinant or synthetic nucleic acids and sequence-specific genome-editing mechanisms. |
Regulatory or Commercial Context | The plans follow a consultation launched in May 2026. Existing approval procedures and standards for quality, safety and efficacy would remain unchanged, and previously authorised products would not require reclassification. |
Potential Impact | If enacted, clearer classification rules could assist development planning and regulatory submissions for emerging genetic medicines without changing the underlying authorisation standards. |
Implementation or Timeline | Government support confirmed on 19 November 2026; amendments remain subject to international notification procedures and parliamentary approval. No effective date has been confirmed. |
Key Takeaway | The UK government supports modernising gene therapy definitions, but the proposed amendments are not yet legislation in force. |
What to Watch | Publication and parliamentary progression of the legislative amendments, completion of international notification procedures and confirmation of implementation guidance and effective dates. |
Primary Source | https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions |
Relevant Date | 19 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments